Abstract
Background and objective
Sickle cell disease (SCD) can predispose patients to avascular necrosis (AVN) of the femoral head, resulting in severe disabling pain. Total hip arthroplasty (THA) is the leading treatment choice for end-stage arthritis caused by AVN. In this study, we aimed to compare complications associated with implant fixation with and without cement.
Materials and methods
We retrospectively analyzed 95 total hip implants in which 26 patients had staged bilateral THA. These surgeries were performed by four senior arthroplasty consultants between 2007 and 2018. Data were collected from the surgical logbook, physical files, and the electronic patient database (I-Seha, National Health Information System, Ministry of Health, Kingdom of Bahrain).
Results
The study included 95 hip implants in 69 patients. Forty-five (47%) were in males, and 50 (53%) were in females. Of these, 22 implants underwent revision (23%), two implants had periprosthetic infections (0.2%), two implants had periprosthetic fractures (0.2%), and 18 implants had implant loosening. We found that cemented THA was significantly associated with the development of implant loosening (p<0.001), small particle disease (p<0.001), and a higher revision rate (p<0.001).
Conclusion
We found that cemented THA in SCD patients led to a higher rate of aseptic implant loosening, mainly caused by osteolysis. Based on our findings, we recommend uncemented THA in SCD patients.
Keywords: cemented total hip arthroplasty, cementless total hip arthroplasty, hip joint pain, avascular necrosis (avn), sickle cell disease
Introduction
Sickle cell disease (SCD) is considered one of the most significant hereditary blood disorders due to its chronic nature and associated high morbidity and mortality. The prevalence of SCD in Bahrain was reported to be 2.1% in a previous neonatal screening study conducted from 1984 to 1985, which is considered high [1]. SCD results from a point mutation in the β-globin chain of hemoglobin replacing the amino acid glutamate with valine at the sixth position. The association of two normal α-globin subunits with two mutant β-globin subunits forms hemoglobin S [2]. This results in hyperplasia of bone marrow, sickling of red blood cells, increased blood viscosity, and eventually arterial occlusion and venous obstruction [3].
Avascular necrosis (AVN) of the femoral head is one of the most disabling sequelae of SCD, with femoral head collapse, arthritis, and debilitating hip pain. The prevalence of AVN in SCD ranges from 10 to 40% [4-6]. Many of these patients are initially asymptomatic. Unmanaged asymptomatic femoral head osteonecrosis in SCD patients has a high risk of advancing to pain and collapse. It has been reported that 95% of the asymptomatic patients with normal radiographs and abnormal MRI became symptomatic with hip pain within three years [7].
Many treatment modalities have been described to treat AVN in various stages of arthritis, including bisphosphonates in the early degenerative phase, as well as operative management with core decompression, rotational osteotomy, and total hip arthroplasty (THA). THA is the leading treatment choice for end-stage arthritis. Due to the young and active nature of patients affected with AVN, high implant-related complications have been reported, mainly due to these patients’ high functional demands [8].
The method of fixation of primary total hip implants is still a matter of controversy. Some prefer using cementing as a method of fixation, while others believe that the uncemented method leads to better functional outcomes and fewer implant-related complications. No definitive piece of evidence has been proposed to establish that one of these methods is superior to the other [9,10]. This paper aims to compare the complications of cemented versus uncemented THA in SCD patients.
Materials and methods
Study design and setting
We retrospectively analyzed 95 THAs in 69 patients. Twenty-six of the patients had staged bilateral THAs. Patients were operated on between 2007 and 2018 by four senior arthroplasty consultants at the Salmaniya Medical Complex, the largest public hospital in Bahrain. All the patients were diagnosed with SCD with advanced AVN of the femur head.
Data were collected from the surgical logbook, physical files, and the electronic patient database (I-Seha, National Health Information System, Ministry of Health, Kingdom of Bahrain). Any short-term or long-term follow-up, such as for superficial or deep tissue infection, deep venous thrombosis, implant failures such as implant loosening, and the need for revision, was also documented. Patients who underwent THA for conditions unrelated to SCD were excluded.
Surgical methods and implant choice
All patients had undergone the procedure using the posterior approach to the hip. All patients had metal on highly cross-linked polyethylene bearings. There was no hybrid fixation in the study population. The use of drains was decided based on the surgeons' preference.
Diagnosing complications
Implant loosening was diagnosed with a plain radiograph and CT scan of the affected hip joint. Physical and electronic files were reviewed to investigate other complications such as periprosthetic infections, periprosthetic fractures, or thromboembolic events.
Statistical analysis
Analysis was conducted using IBM SPSS Statistics version 28 (IBM Corp., Armonk, NY). To summarize the data, descriptive statistics were utilized, and the frequencies and proportions were calculated for the demographic and clinical characteristics of the study population. Furthermore, a Chi-square test of independence was performed to analyze the relationship between the type of fixation and complications and to analyze risk factors predisposing to revision surgery.
Results
The study included a total of 95 hip implants in 69 patients. Forty-five (47%) were in males, and 50 (53%) were in females. Twenty-six patients had staged bilateral THAs. Fifty-five (58%) implants used uncemented fixation, and 40 implants had cemented fixation (42%). A total of 22 implants underwent revision (23%), two (2%) implants had periprosthetic infections, two (2%) had periprosthetic fractures, and 18 implants had implant loosening (Table 1). A total of 22 (23.16%) implants had evidence of implant loosening on the CT scan of the hip joint, four (4.21%) implants had femoral component loosening, five (5.26%) implants had acetabular cup loosening, and 13 (13.68%) implants experienced loosening of both components. Eighteen (18.95%) implants with implant loosening underwent revision surgery, but four did not.
Table 1. Demographic and clinical characteristics of the study population (n=95 implants, 69 patients).
Variable | Level | Number of implants | Proportion |
Gender | Male | 45 | 0.47 |
Female | 50 | 0.53 | |
Cemented/uncemented | Uncemented | 55 | 0.58 |
Cemented | 40 | 0.42 | |
Periprosthetic infection | No | 93 | 0.98 |
Yes | 2 | 0.02 | |
Revision | No | 73 | 0.77 |
Yes | 22 | 0.23 | |
Osteolysis | No | 78 | 0.82 |
Yes | 17 | 0.18 | |
Component loosening | No | 73 | 0.77 |
Yes | 22 | 0.23 |
We found a statically significant association between cemented THA and the development of implant loosening (p<0.001), small particle disease (p<0.001), and a higher revision rate (p<0.001) (Table 2).
Table 2. Comparison between the rate of complications in cemented and uncemented hip replacement.
Variable | Level | Uncemented | Cemented | χ² | P-value | |
Periprosthetic fracture | No | Observed | 55 | 38 | 2.81 | 0.094 |
Expected | 53.84 | 39.16 | ||||
Yes | Observed | 0 | 2 | |||
Expected | 1.16 | 0.84 | ||||
Revision | No | Observed | 49 | 24 | 11.01 | <0.001* |
Expected | 42.26 | 30.74 | ||||
Yes | Observed | 6 | 16 | |||
Expected | 12.74 | 9.26 | ||||
Osteolysis | No | Observed | 53 | 25 | 18.07 | <0.001* |
Expected | 45.16 | 32.84 | ||||
Yes | Observed | 2 | 15 | |||
Expected | 9.84 | 7.16 | ||||
Component loosening | No | Observed | 49 | 24 | 11.01 | <0.001* |
Expected | 42.26 | 30.74 | ||||
Yes | Observed | 6 | 16 | |||
Expected | 12.74 | 9.26 | ||||
Small particle disease | No | Observed | 55 | 35 | 7.26 | 0.007* |
Expected | 52.11 | 37.89 | ||||
Yes | Observed | 0 | 5 | |||
Expected | 2.89 | 2.11 | ||||
Dislocation | No | Observed | 54 | 40 | 0.74 | 0.391 |
Expected | 54.42 | 39.58 | ||||
Yes | Observed | 1 | 0 | |||
Expected | 0.58 | 0.42 | ||||
Thromboembolic event | No | Observed | 55 | 39 | 1.39 | 0.238 |
Expected | 54.42 | 39.58 | ||||
Yes | Observed | 0 | 1 | |||
Expected | 0.58 | 0.42 |
Furthermore, we investigated factors leading to revision surgery and found it to be statistically significantly associated with cemented fixation (p<0.001), osteolysis (p<0.001), and component loosening (p<0.001) (Table 3).
Table 3. Analysis of the factors predisposing to revision surgery.
Variable | Level | Revision | χ² | P-value | ||
No | Yes | |||||
Gender | Male | Observed | 31 | 14 | 3.04 | 0.081 |
Expected | 34.58 | 10.42 | ||||
Female | Observed | 42 | 8 | |||
Expected | 38.42 | 11.58 | ||||
Periprosthetic infection | No | Observed | 73 | 20 | 6.78 | 0.009* |
Expected | 71.46 | 21.54 | ||||
Yes | Observed | 0 | 2 | |||
Expected | 1.54 | 0.46 | ||||
Periprosthetic fracture | No | Observed | 73 | 20 | 6.78 | 0.009* |
Expected | 71.46 | 21.54 | ||||
Yes | Observed | 0 | 2 | |||
Expected | 1.54 | 0.46 | ||||
Cemented | No | Observed | 49 | 6 | 11.01 | <0.001* |
Expected | 42.26 | 12.74 | ||||
Yes | Observed | 24 | 16 | |||
Expected | 30.74 | 9.26 | ||||
Osteolysis | No | Observed | 69 | 9 | 33.07 | <0.001* |
Expected | 59.94 | 18.06 | ||||
Yes | Observed | 4 | 13 | |||
Expected | 13.06 | 3.94 | ||||
Component lessening | No | Observed | 69 | 4 | 55.36 | <0.001* |
Expected | 56.09 | 16.91 | ||||
Yes | Observed | 4 | 18 | |||
Expected | 16.91 | 5.09 | ||||
Small particle disease | No | Observed | 72 | 18 | 9.58 | <0.001* |
Expected | 69.16 | 20.84 | ||||
Yes | Observed | 1 | 4 | |||
Expected | 3.84 | 1.16 | ||||
Dislocation | No | Observed | 73 | 21 | 3.35 | 0.067 |
Expected | 72.23 | 21.77 | ||||
Yes | Observed | 0 | 1 | |||
Expected | 0.77 | 0.23 | ||||
Thromboembolic events | No | Observed | 73 | 21 | 3.35 | 0.067 |
Expected | 72.23 | 21.77 | ||||
Yes | Observed | 0 | 1 | |||
Expected | 0.77 | 0.23 |
One (1.05%) implant had deep venous thromboembolism, and no implants had heterotopic ossifications or intraoperative periprosthetic fracture. Eighty-six implants had a drain placed intraoperatively, and only nine (9.47%) implants did not have a drain placed.
Discussion
Fixation of hip implants can be classified into either cemented fixation using polymethylmethacrylate or biologic uncemented fixation relying on bone ingrowth and ongrowth. Several studies have concluded that cementless hip arthroplasty is superior to the cemented method. A couple of papers have cited results that prove that cemented hip arthroplasties lead to more complications than cementless ones [11-13]. With trends leaning toward the biological fixation of hip implants, this study aimed to investigate the complications associated with the method of fixation of total hip implants in SCD patients.
Unlike osteoarthritis (OA) patients who receive THA, patients with SCD have elevated risks of complications following this procedure. A retrospective study involving 881 patients found a higher rate of aseptic loosening (1.94%) in patients with SCD compared to patients with AVN without SCD (0.68%; p=0.021) [14].
Good outcomes were reported following uncemented THAs in a study by Ilyas et al., which reported 133 uncemented THAs with a mean follow-up of 14.6 years and a 94.1% survival rate at 15 years [15]. Azam and Sadat-Ali assessed 87 cementless procedures and reported a survival rate of 92.6% at 7.5 years [16]. Although these two papers followed only uncemented fixation, their results are in agreement with our findings in terms of higher implant survival in uncemented patients.
Several papers have described various concepts with regard to THA in SCD patients, including the systematic review conducted by Kenanidis et al. Their study's findings are in agreement with ours, revealing a higher rate of revision in cemented THA (48 out of 312 cemented THAs were revised at a mean of 13 years versus 14 out of 133 uncemented THAs at a mean of 14.6 years) [17]. Similarly, AlOmran compared cemented versus uncemented THAs and found that 61% (p=0.001) of the cemented implants failed compared to 22.3% of the uncemented implants [12].
This study has a few limitations, primarily related to lost details and data; moreover, its retrospective design proved to be an obstacle in documenting the functional status of the patients pre-and postoperatively. Additionally, the two groups of patients were operated on by different surgeons, and factors such as surgical techniques may have influenced the results. Finally, it was not documented if different implant brands were used, and this may have been a confounding factor.
Conclusions
THA is the preferred management of choice for patients with advanced AVN secondary to SCD. The primary goal of this procedure is to alleviate hip pain and improve the range of motion of the hip joint. However, elevated complications associated with SCD might affect the quality of life following this procedure; hence, eliminating factors related to these complications might aid in improving outcomes postoperatively. We found that cemented THA in SCD patients led to a higher rate of aseptic implant loosening, mainly caused by osteolysis. Furthermore, cemented fixation technique resulted in a higher rate of revision surgery. In light of our results, we recommend the use of uncemented fixation for total hip implants in SCD patients.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Campaign to control genetic blood diseases in Bahrain. Al Arrayed S. Community Genet. 2005;8:52–55. doi: 10.1159/000083340. [DOI] [PubMed] [Google Scholar]
- 2.Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease. Kamath AF, McGraw MH, Israelite CL. World J Orthop. 2015;6:776–782. doi: 10.5312/wjo.v6.i10.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bone involvement in sickle cell disease. Almeida A, Roberts I. Br J Haematol. 2005;129:482–490. doi: 10.1111/j.1365-2141.2005.05476.x. [DOI] [PubMed] [Google Scholar]
- 4.Sickle cell disease as a cause of osteonecrosis of the femoral head. Milner PF, Kraus AP, Sebes JI, et al. N Engl J Med. 1991;325:1476–1481. doi: 10.1056/NEJM199111213252104. [DOI] [PubMed] [Google Scholar]
- 5.Deformities of the hip in adults who have sickle-cell disease and had avascular necrosis in childhood. A natural history of fifty-two patients. Hernigou P, Galacteros F, Bachir D, Goutallier D. https://pubmed.ncbi.nlm.nih.gov/1985998/ J Bone Joint Surg Am. 1991;73:81–92. [PubMed] [Google Scholar]
- 6.Sickle cell disease and silent avascular necrosis of the hip. Ware HE, Brooks AP, Toye R, Berney SI. J Bone Joint Surg Br. 1991;73:947–949. doi: 10.1302/0301-620X.73B6.1955442. [DOI] [PubMed] [Google Scholar]
- 7.The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. Hernigou P, Habibi A, Bachir D, Galacteros F. J Bone Joint Surg Am. 2006;88:2565–2572. doi: 10.2106/JBJS.E.01455. [DOI] [PubMed] [Google Scholar]
- 8.Total THA in adult osteonecrosis related to sickle cell disease. Hernigou P, Zilber S, Filippini P, Mathieu G, Poignard A, Galacteros F. Clin Orthop Relat Res. 2008;466:300–308. doi: 10.1007/s11999-007-0069-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Comparison of total hip arthroplasty performed with and without cement: a randomized trial. Laupacis A, Bourne R, Rorabeck C, Feeny D, Tugwell P, Wong C. J Bone Joint Surg Am. 2002;84:1823–1828. doi: 10.2106/00004623-200210000-00013. [DOI] [PubMed] [Google Scholar]
- 10.Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomised clinical study. Kim YH, Oh SH, Kim JS. https://pubmed.ncbi.nlm.nih.gov/12892186/ J Bone Joint Surg Br. 2003;85:661–665. [PubMed] [Google Scholar]
- 11.Operating time and survival of primary total hip replacements: an analysis of 31,745 primary cemented and uncemented total hip replacements from local hospitals reported to the Norwegian Arthroplasty Register 1987-2001. Småbrekke A, Espehaug B, Havelin LI, Furnes O. Acta Orthop Scand. 2004;75:524–532. doi: 10.1080/00016470410001376. [DOI] [PubMed] [Google Scholar]
- 12.Choice of implant in total hip arthroplasty for sickle cell disease patients. AlOmran AS. Eur Orthop Traumatol. 2010;1:25–29. [Google Scholar]
- 13.What works best, a cemented or cementless primary total hip arthroplasty?: minimum 17-year followup of a randomized controlled trial. Corten K, Bourne RB, Charron KD, Au K, Rorabeck CH. Clin Orthop Relat Res. 2011;469:209–217. doi: 10.1007/s11999-010-1459-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Impact of sickle cell disease on postoperative outcomes following total hip arthroplasty. Gu A, Agarwal AR, Fassihi SC, et al. Hip Int. 2021;2:3–7. doi: 10.1177/11207000211052224. [DOI] [PubMed] [Google Scholar]
- 15.Noncemented total hip arthroplasty in sickle-cell disease: long-term results. Ilyas I, Alrumaih HA, Rabbani S. J Arthroplasty. 2018;33:477–481. doi: 10.1016/j.arth.2017.09.010. [DOI] [PubMed] [Google Scholar]
- 16.Quality of life in sickle cell patients after cementless total hip arthroplasty. Azam MQ, Sadat-Ali M. J Arthroplasty. 2016;31:2536–2541. doi: 10.1016/j.arth.2016.04.025. [DOI] [PubMed] [Google Scholar]
- 17.Total hip arthroplasty in sickle cell disease: a systematic review. Kenanidis E, Kapriniotis K, Anagnostis P, Potoupnis M, Christofilopoulos P, Tsiridis E. EFORT Open Rev. 2020;5:180–188. doi: 10.1302/2058-5241.5.190038. [DOI] [PMC free article] [PubMed] [Google Scholar]